ArticleDiabetology & metabolic syndrome2025
Empagliflozin targeted the immune-related gene PIK3CA in type 2 diabetes mellitus treatment: network pharmacology analysis and experimental evidence.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Empagliflozin in the Absence of Diabetes: A Systematic Review of Its Anthropometric and Metabolic Effects in Humans and Animals.International journal of endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundType 2 diabetes mellitus (T2DM) is linked to elevated blood glucose due to insulin resistance. Empagliflozin has demonstrated efficacy in T2DM management, with potential immune-modulatory effects. This study aimed to investigate the immune-related mechanisms of empagliflozin in T2DM treatment.
methodsGene expression profiles were obtained from common databases, and immune-related differentially expressed genes (IRDEGs) were identified using the "limma" R package. The STRING database and Cytoscape software were utilized to construct a protein-protein interaction network and identify key IRDEGs. Molecular docking was performed to predict the interaction between empagliflozin and PIK3CA. Pathways related to PIK3CA were explored using GSEA, and relationship of PIK3CA with immune cells was analyzed using single-cell RNA sequencing analysis. The effects of empagliflozin on high glucose-induced RAW264.7 macrophages and PI3K/AKT signaling were assessed using CCK-8, fluorescence detection, qRT-PCR, and Western blotting.
resultsWe identified 109 IRDEGs in T2DM, with PIK3CA as a key gene. Empagliflozin showed binding affinity to PIK3CA, which was linked to immune cell interactions and inflammatory responses. Single-cell RNA sequencing analysis revealed the interaction of PIK3CA with macrophages. In high glucose-induced RAW264.7 macrophages, PIK3CA expression was elevated. Empagliflozin ameliorated the high glucose-induced cell injury and inhibited the expression of PIK3CA in macrophages. Additionally, empagliflozin treatment reduced the expression of CD44 and ITGAV, IL-6, and TNF-α, and increased the p-PI3K/PI3K ratio.
conclusionEmpagliflozin's therapeutic effects in T2DM may be mediated through the modulation of immune pathways, particularly by targeting PIK3CA within the PI3K/AKT signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.